New combo pill showdown: which diabetes cocktail wins?
NCT ID NCT07442006
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests four different drug combinations in 178 adults with type 2 diabetes whose blood sugar is not well controlled on metformin and an SGLT-2 inhibitor. Over 12 weeks, researchers will measure how much and how often blood sugar swings. The goal is to find which combo offers the steadiest glucose levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Empagliflozin/Metformin, Anagliptin, Metformin, Empagliflozin/Linagliptin
What this could lead to
If successful, this could show which drug combination best stabilizes blood sugar and improves daily glucose control for people with type 2 diabetes.
What could go wrong
This is a mid-stage trial with only 178 participants over 12 weeks, so results may not apply to everyone. Side effects like kidney issues or metabolic acidosis are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Catholic University of Korea, Bucheon St. Mary's Hospital, Principal Investigator
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••